Loading patent…
AssigneeCentre Hospitalier Universitaire De Bordeaux
InventorsJEAN-FRANCOIS AUGUSTO, CECILE CONTIN-BORDES, YAHSOU DELMAS, PATRICK BLANCO, YVES DELNESTE, PASCALE JEANNIN, CELINE BEAUVILLAIN
Estimating the term…
The present invention concerns clusterin for use in the treatment of thrombotic microangiopathies, and a pharmaceutical composition comprising clusterin for use in the treatment of thrombotic microangiopathies, said composition not comprising von Willebrand factor protease. The present invention also concerns an ex vivo method for stratifying a patient suffering, or likely to be suffering, from TMA, comprising the following steps: 1) measuring, in a biological sample from said patient, the amount LC of clusterin, and 2) comparing the amount Lc measured in step 1) with an amount Lref of clusterin by calculating the score S1=LC/Lref, in which: •If S1≤1, the patient is considered to be likely to benefit from a treatment of the TMA with clusterin, •If S1>1, the patient is not considered to be likely to benefit from treatment of TMA with clusterin.
A method of treating a thrombotic microangiopathy comprising administering a therapeutically effective amount of clusterin to a subject in need of such treatment.
The method of claim, wherein said clusterin is a recombinant clusterin, a plasma clusterin, or a synthetic clusterin.
A pharmaceutical composition comprising clusterin, said composition not comprising von Willebrand factor of protease.
An ex vivo method for stratification of a patient who is or who may be suffering from a thrombotic microangiopathy (TMA), comprising the following steps:
Dependencies are inferred from the claim text.